Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe [Yahoo! Finance]
Xenon Pharmaceuticals Inc. - Common Shares (XENE)
Last xenon pharmaceuticals inc. - common shares earnings: 11/5 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.xenon-pharma.com
Company Research
Source: Yahoo! Finance
At present, the company has no marketed drug in its portfolio. Xenon's pipeline comprises its lead product candidate, azetukalner, a differentiated Kv7 potassium channel, which is being developed for treating epilepsy and other neurological disorders, including major depressive disorder (MDD). Azetukalner is currently undergoing late-stage development for treating focal onset seizures (FOS). Under the phase III epilepsy program, two identical phase III studies, X-TOLE2 and X-TOLE3, are evaluating 15 mg or 25 mg doses of azetukalner, administered with food as adjunctive treatment in patients with FOS. The first top-line data readout from the X-TOLE2 study is anticipated in the second half of 2025. Xenon plans to submit a regulatory application seeking approval of azetukalner for FOS, contingent upon the success of the X-TOLE2 study. The company is also evaluating azetukalner for an additional epilepsy indication, primary generalized tonic-clonic seizures, in a phase III X-ACKT
Show less
Read more
Impact Snapshot
Event Time:
XENE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XENE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XENE alerts
High impacting Xenon Pharmaceuticals Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
XENE
News
- Xenon to Report Q3 2024 Financial Results on November 12, 2024 [Canadian Business Journal (Canada)]Canadian Business Journal
- Xenon to Report Q3 2024 Financial Results on November 12, 2024GlobeNewswire
- Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $50.00 price target on the stock.MarketBeat
- Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual ConferenceGlobeNewswire
- Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $53.00 price target on the stock.MarketBeat
XENE
Earnings
- 8/8/24 - Miss
XENE
Sec Filings
- 8/9/24 - Form S-3ASR
- 8/8/24 - Form 10-Q
- 8/8/24 - Form 8-K
- XENE's page on the SEC website